ジーエヌアイグループ（2160） – First Subject Enrolled for Phase III Clinical Trial of Pirfenidone Capsules (F647) for Treatment of Pneumoconiosis

June 13th, 2022 Company Name: GNI Group Ltd. Representative: Director, Representative Executive Officer, Contact Person: Director, Executive Officer, CFO President and CEO Ying Luo, PhD (Security Code: 2160, TSE Growth) Joseph Francis Meyer (TEL. 03-6214-3600) First Subject Enrolled for Phase III Clinical Trial of Pirfenidone Capsules (F647) for Treatment of Pneumoconiosis Beijing Continent Pharmaceutical Co., Ltd. (hereinafter referred to as Beijing Continent), one of the consolidated subsidiaries of GNI Group Ltd. (hereinafter referred to as the Group), announced that it had enrolled on June 7th the first subject in Phase III clinical trial of the Pirfenidone Capsules (F647) for pneumoconiosis. Beijing Continent has been working on the clinical trials for pneumoconiosis as the fifth indication of ETUARY® (generic name: pirfenidone), which is the main product of Beijing Continent, as published in the past Group’s consolidated financial result disclosures. Pneumoconiosis is a general term for a group of occupational lung diseases mainly characterized by diffuse fibrosis (scar) of lung tissue associated with the long-term inhalation and deposition of different pathogenic production dusts in the lungs during occupational activities. It is still the most serious and common occupational disease in China. The Pirfenidone Capsules (F647) is a small molecule oral drug that inhibits collagen synthesis and reduce fibrous hyperplasia by regulating such cytokines as TGF-β (transforming growth factor-β). In the Phase III Clinical Trial of F647, the efficacy and safety of F647 in the treatment of pneumoconiosis will be confirmed. For more details, please refer to the article dated June 13th, 2022 on the Beijing Continent’s website below. https://www.bjcontinent.com/en/news About GNI Group, Inc. GNI Group is a global healthcare company listed on the Growth Board of the Tokyo Stock Exchange and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China. For more information, please visit our website below https://www.gnipharma.com/ This document is a press release material created purely for the purpose of publicly disclosing Beijing Continent’s notice on their website and NOT for the purpose of soliciting investment either in Japan or overseas.